Vivo Bio Tech Ltd
VIVOBIOTVivo Bio Tech Ltd
VIVOBIOT
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 7.98 | 1.10 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.70 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Vivo Bio Tech Limited is a biotechnology company that operates as a contract research organization (CRO) offering drug development and discovery services. It offers services in the areas of In vitro, In vivo, toxicity studies etc.
Peers
Compare with peersBiocon Ltd
Panacea Biotec Ltd
Hester Biosciences Ltd
Zenotech Laboratories Ltd
Transgene Biotek Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 29.47 | 34.53 | 47.13 | 55.84 | 55.40 | 51.86 | 51.49 | 52.27 | 45.49 | 51.47 | ||||||||||
Raw Materials | 8.19 | 8.62 | 12.60 | 12.41 | 10.90 | 9.91 | 7.97 | 4.93 | 4.65 | 25.07 | ||||||||||
| Power & Fuel Cost | 2.46 | 2.91 | 2.87 | 2.93 | 4.69 | 5.78 | 3.56 | 4.27 | 3.93 | |||||||||||
| Employee Cost | 4.34 | 5.50 | 7.66 | 9.58 | 10.00 | 8.57 | 9.42 | 13.52 | 10.68 | |||||||||||
| Selling & Administrative Expenses | 6.53 | 8.14 | 12.33 | 12.30 | 8.75 | 11.78 | 9.99 | 4.79 | 5.03 | |||||||||||
| Operating & Other expenses | 3.36 | 1.33 | 0.66 | 9.10 | 8.54 | -2.07 | 4.36 | 2.88 | -0.10 | |||||||||||
EBITDA | 4.59 | 8.03 | 11.01 | 9.52 | 12.52 | 17.89 | 16.19 | 21.88 | 21.30 | 26.40 | ||||||||||
| Depreciation/Amortization | 3.35 | 3.90 | 4.64 | 5.06 | 5.17 | 5.59 | 7.45 | 9.27 | 9.29 | 9.23 | ||||||||||
| PBIT | 1.24 | 4.13 | 6.37 | 4.46 | 7.35 | 12.30 | 8.74 | 12.61 | 12.01 | 17.17 | ||||||||||
| Interest & Other Items | 0.47 | 1.29 | 2.37 | 2.64 | 3.10 | 3.67 | 4.27 | 7.99 | 7.95 | 7.72 | ||||||||||
| PBT | 0.77 | 2.84 | 4.00 | 1.82 | 4.25 | 8.63 | 4.47 | 4.62 | 4.06 | 9.45 | ||||||||||
| Taxes & Other Items | -0.13 | 0.33 | 0.88 | -0.42 | -0.19 | 2.94 | 2.27 | 1.97 | 1.54 | 1.98 | ||||||||||
| Net Income | 0.90 | 2.51 | 3.12 | 2.24 | 4.44 | 5.69 | 2.20 | 2.65 | 2.52 | 7.47 | ||||||||||
| EPS | 0.96 | 2.68 | 3.25 | 2.02 | 3.52 | 4.33 | 1.59 | 1.82 | 1.69 | 5.01 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vivo Bio Tech Ltd | 23.64 | 1.10 | — |
| Biocon Ltd | 38.30 | 1.55 | 0.15% |
| Panacea Biotec Ltd | -2,064.01 | 2.86 | — |
| Hester Biosciences Ltd | 109.80 | 6.84 | 0.25% |
Price Comparison
Compare VIVOBIOT with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
VIVOBIOT has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeVivo Bio Tech will hold a meeting of the Board of Directors of the Company on 21 November 2024Powered by Capital Market - Live
Net profit of Vivo Bio Tech rose 1484.85% to Rs 5.23 crore in the quarter ended September 2024 as against Rs 0.33 crore during the previous quarter ended September 2023. Sales rose 30.02% to Rs 12.04 crore in the quarter ended September 2024 as against Rs 9.26 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales12.049.26 30 OPM %46.4352.48 - PBDT8.162.77 195 PBT5.870.46 1176 NP5.230.33 1485 Powered by Capital Market - Live
Vivo Bio Tech will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Vivo Bio Tech announced that the 37th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Net profit of Vivo Bio Tech rose 21.43% to Rs 0.17 crore in the quarter ended June 2024 as against Rs 0.14 crore during the previous quarter ended June 2023. Sales declined 12.52% to Rs 10.13 crore in the quarter ended June 2024 as against Rs 11.58 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales10.1311.58 -13 OPM %43.1438.77 - PBDT2.452.54 -4 PBT0.220.25 -12 NP0.170.14 21 Powered by Capital Market - Live
Vivo Bio Tech will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -4.02%, vs industry avg of 19.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.81% to 0.27%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 2.38%, vs industry avg of 1.42%